I-STAR Technology

Theraclone’s approach to therapeutic mAb discovery is unique as it enables the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biological functions and activities. These antibodies can be further developed as therapeutic candidates or can form the basis for engineering including antibody drug conjugation (ADC), bispecificity, CAR-T therapy or vector delivery. The process also facilitates the discovery of novel targets that may be drugable or can be exploited for vaccine development. Successful partnerships and a strong Research and Development pipeline have repeatedly validated Theraclone’s platform technology.

I-STAR™ Proven mAb Discovery Platform

I-STAR Technology


We have leveraged I-STAR technology and our antibody discovery expertise to identify potential product candidates to treat influenza, bacterial infections and various cancers.


We have also formed strategic partnerships using our I-STAR technology including: